Friday, April, 19, 2019 05:18:50

Global Blood Preparation Market is set to exceed USD 78.5 billion by 2025; according to a new research report by Global Market Insights. Rising prevalence of blood related disorders requiring blood transfusion will act as high impact rendering factor for blood preparation market growth during the forecast timeframe. Outbreak of infectious diseases such as dengue fever leads to rise in demand for platelet products and transfusion. South-east Asian countries such as Indonesia, India, Thailand and Myanmar are at highest risk of disease incidence. Strong product pipeline of anti-thrombotic and anticoagulant drugs coupled with rising awareness about blood donation in developing countries should propel industry growth. Furthermore, increasing number of road and occupational accidents should stimulate demand for blood and blood components leading to business growth.

Growing geriatric population base, generally suffering from chronic conditions such as liver cirrhosis will positively impact blood preparation market growth. Expanded applications of blood derivatives including application of platelet rich plasma in anti-aging therapy should boost business growth over the forecast period. However, risk of disease transmission such as syphilis, HIV, Hepatitis B and C, AIDS resulting due to blood transfusion will limit industry expansion to certain extent over the coming years.

Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/790

As per WHO’s statistics, approximately 112.5 million blood donations are collected across the world, per year. The major origin of this volume is from high-income countries which account for nearly 50% of the total collection. The blood can be transfused to the patient in either an unmodified state or can be utilized more efficiently by processing it into components such as platelet concentrates, red cell concentrates, cryoprecipitate, and plasma. In the latter scenario, the sample can be utilized by more than one patient. However, the former known as ‘Whole Blood’ dominated the product landscape of the blood preparation industry by contributing to 48% of the overall volume in 2015. This was followed by the second most popular product- blood derivatives which held 34% of the global blood preparation market share in the same year.

Research also depicts the differences in the transfused patient base category and the applications relevant to the different geographies, which impacts the overall blood preparation industry dynamics. For instance, in high-income countries, the transfused patient base majorly falls in the category of geriatric population accounting for over 76% of the overall transfusion. The transfusions in these regions are mostly carried out for cardiovascular surgeries, massive trauma, transplant surgeries, and hematological disorders. On these grounds, the U.S. will lead blood preparation industry having registered a massive revenue of USD 19 billion in 2015. The region is forecast to record a growth rate of 3.5% over 2016-2024. Supportive regulatory framework across the U.S. is also a leading factor driving the regional demand. For instance, FDA monitors the collection, storage, and transport of blood and works in partnership with health insurance agencies to implement optimal reimbursement for blood components.

As per CDC, 1-2 of every 1000 people in the U.S. are detected with DVT (Deep Brain Thrombosis) or PE (Pulmonary Embolism) annually. As per the estimates, the two aforementioned ailments are listed as the leading causes of demises and dominated the application landscape of the blood preparation market in 2015. Reportedly, Thrombocytosis and Pulmonary Embolism together accounted for 43% of the overall blood preparation industry size in 2015.

The top-notch companies engaged in this business space including- Pfizer, AstraZeneca, GlaxoSmithKline, Leo Pharma, Sanofi, Celgene, Bristol-Myers, and Baxter Healthcare are constantly making efforts to diversify their products and services in sync with the fast-paced technological developments and the demand of the increasing patient base. The companies are investing heavily in R&D to develop novel, efficient, and affordable anticoagulants and antithrombotic drugs. In 2015, anticoagulants led the blood preparation industry landscape holding a revenue of USD 17 billion.

The robust investments in healthcare infrastructure development will further lead to a remarkable expansion of blood preparation market in Europe and Asia Pacific. Europe market share is claimed to be prominently driven by France and Germany, slated to register CAGR of 2.3% and 1.8% respectively. APAC blood preparation industry will also witness substantial growth over the coming years driven by the favorable health norms and technological advancements in healthcare across this region. China, India, and Japan are slated to be the chief revenue pockets for APAC. As per estimates, Japan blood preparation market will register an annual growth rate of 5.9% over 2016-2024.

Make an inquiry for purchasing this report @ https://www.gminsights.com/inquiry-before-buying/790

Few notable players operating in blood preparation market are Bayer, Aralez Pharmaceuticals, Pfizer, GlaxoSmithKline, AstraZeneca, Ionis Pharmaceuticals, Leo Pharma, Boehringer Ingelheim, Daiichi Sankyo, Bristol-Myers, Johnson and Johnson among other players. Industry players are adopting various organic and inorganic strategies to consolidate their market position and expand product portfolio. Companies are investing heavily in research and development. Bayer and Ionis have invested into development of IONIS-FXIRX, a second-generation antisense anticoagulant drug that is currently undergoing Phase II clinical trials.